BioVaxys Technology Corp.

Clinical-stage immunotherapy development in oncology and infectious disease.

CSE · OTCQBLife Sciences2 reports

Reporting archive

Latest $BIOV coverage

January 29, 2026

Life Sciences

Five of 17 evaluable subjects achieved objective responses, including two confirmed complete responses, in a Phase 2 combination study.

January 20, 2026

Life Sciences

The PESCO study evaluated MVP-S with pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer.